Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Nanoscale structure of amyloid-β plaques in Alzheimer's disease

  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Colom-Cadena, Martí|||0000-0002-8514-4534
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Núñez-Llaves, Raúl|||0000-0002-6702-4774
  • Luque-Cabecerans, Joan
  • Muñoz, Laia|||0000-0003-0578-3094
  • Andilla, Jordi
  • Belbin, Olivia|||0000-0002-6109-6371
  • Spires-Jones, T. L.|||0000-0003-2530-0598
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Loza-Alvarez, Pablo|||0000-0002-3129-1213
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Soluble amyloid-β (Aβ) is considered to be a critical component in the pathogenesis of Alzheimer's disease (AD). Evidence suggests that these non-fibrillar Aβ assemblies are implicated in synaptic dysfunction, neurodegeneration and cell death. However, characterization of these species comes mainly from studies in cellular or animal models, and there is little data in intact human samples due to the lack of adequate optical microscopic resolution to study these small structures. Here, to achieve super-resolution in all three dimensions, we applied Array Tomography (AT) and Stimulated Emission Depletion microscopy (STED), to characterize in postmortem human brain tissue non-fibrillar Aβ structures in amyloid plaques of cases with autosomal dominant and sporadic AD. Ultrathin sections scanned with super-resolution STED microscopy allowed the detection of small Aβ structures of the order of 100 nm. We reconstructed a whole human amyloid plaque and established that plaques are formed by a dense core of higher order Aβ species (~0.022 µm ) and a peripheral halo of smaller Aβ structures (~0.003 µm ). This work highlights the potential of AT-STED for human neuropathological studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease

  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Suárez Calvet, Marc|||0000-0002-2993-569X
  • Muñoz, Laia|||0000-0003-0578-3094
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Subirana, Andrea
  • Querol-Vilaseca, Marta|||0000-0002-8589-1636
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Ribosa-Nogué, Roser|||0000-0002-9233-4336
  • Blesa, Rafael|||0000-0003-4026-2884
  • Haass, Christian|||0000-0002-4869-1627
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
The role of innate immunity in dementia with Lewy bodies (DLB) has been little studied. We investigated the levels in cerebrospinal fluid (CSF) of glial proteins YKL-40, soluble TREM2 (sTREM2) and progranulin in DLB and their relationship with Alzheimer's disease (AD) biomarkers. We included patients with DLB (n = 37), prodromal DLB (prodDLB, n = 23), AD dementia (n = 50), prodromal AD (prodAD, n = 53), and cognitively normal subjects (CN, n = 44). We measured levels of YKL-40, sTREM2, progranulin, Aβ, total tau (t-tau) and phosphorylated tau (p-tau) in CSF. We stratified the group DLB according to the ratio t-tau/Aβ (≥0.52, indicative of AD pathology) and the A/T classification. YKL-40, sTREM2 and progranulin levels did not differ between DLB groups and CN. YKL-40 levels were higher in AD and prodAD compared to CN and to DLB and prodDLB. Patients with DLB with a CSF profile suggestive of AD copathology had higher levels of YKL-40, but not sTREM2 or PGRN, than those without. T+ DLB patients had also higher YKL-40 levels than T-. Of these glial markers, only YKL-40 correlated with t-tau and p-tau in DLB and in prodDLB. In contrast, in prodAD, sTREM2 and PGRN also correlated with t-tau and p-tau. In conclusion, sTREM2 and PGRN are not increased in the CSF of DLB patients. YKL-40 is only increased in DLB patients with an AD biomarker profile, suggesting that the increase is driven by AD-related neurodegeneration. These data suggest a differential glial activation between DLB and AD.